Suboxone Maintenance Dose
The recommended maintenance dose of Suboxone (buprenorphine/naloxone) for adults with opioid use disorder is 16 mg daily, with an effective range of 12-24 mg per day administered as a single daily dose. 1
Target Dosing
The FDA-approved labeling establishes 16 mg/day as the target maintenance dose 1. Clinical trials demonstrate that:
- 16 mg is clinically effective compared to placebo with high-quality evidence 2
- Doses as low as 12 mg may be effective in some patients 1
- The therapeutic range extends from 4-24 mg daily depending on individual patient needs 1
Dose-Response Relationship
The evidence reveals a clear dose-dependent effect on treatment outcomes:
For withdrawal suppression alone: Lower doses (4-8 mg) may suffice, requiring ≤50% mu-opioid receptor occupancy 3
For blocking illicit opioid effects: Higher doses are essential. Only buprenorphine ≥16 mg effectively suppresses illicit opioid use (high-quality evidence), while low-dose (2-6 mg) and medium-dose (7-15 mg) buprenorphine showed no superiority over placebo in preventing illicit opioid use 2. This blockade requires <20% mu-opioid receptor availability, associated with trough plasma concentrations ≥3 ng/mL 3.
Dosing Algorithm
Induction (Days 1-3):
- Day 1: 8 mg buprenorphine (Subutex preferred to avoid precipitated withdrawal)
- Day 2: 16 mg buprenorphine
- Day 3 onward: Switch to Suboxone at same dose 1
Maintenance adjustment:
- Titrate in 2-4 mg increments/decrements 1
- Target: The dose that holds the patient in treatment AND suppresses opioid withdrawal 1
- For most patients, this requires 16 mg or higher 1, 2
Critical Considerations in the Fentanyl Era
Recent evidence suggests higher doses (>24 mg) may be increasingly necessary given fentanyl predominance 4. However, concerning trends show the proportion of treatment episodes with doses <16 mg actually increased from 34.1% in 2019 to 39.2% in 2021—moving in the wrong direction as the opioid supply became more potent 4.
For patients with inadequate response to standard dosing:
- Consider doses up to 24 mg (upper FDA-approved range) 1
- If 24 mg proves insufficient, transition to methadone maintenance should be considered 5
- Some evidence supports even higher buprenorphine doses in select cases, though this exceeds standard labeling 3
Comparison to Methadone
When comparing flexible-dose regimens, methadone retains more patients in treatment than buprenorphine (high-quality evidence) 2. However, at fixed medium (7-15 mg buprenorphine vs 40-85 mg methadone) and high doses (≥16 mg buprenorphine vs ≥85 mg methadone), no difference exists in retention or suppression of illicit opioid use 2.
Common Pitfalls to Avoid
Underdosing is the most critical error. Many clinicians stop at 8-12 mg, which may prevent withdrawal but fails to provide adequate receptor blockade against illicit opioid use 2, 3. The evidence unequivocally shows that doses below 16 mg do not effectively suppress illicit opioid use compared to placebo 2.
Arbitrary dose limits imposed by payers or institutional policies are unwarranted and contradict the evidence 3. Fixed limits fail to account for individual pharmacokinetic variability, severity of dependence, and the potency of currently available illicit opioids.
Premature discontinuation when patients report feeling "stable" at lower doses—stability in terms of withdrawal suppression does not equal adequate protection against relapse 3.
Administration Details
- Sublingual administration only—tablets must dissolve completely under the tongue 1
- Swallowing reduces bioavailability significantly 1
- For doses requiring >2 tablets, place all at once or two at a time until complete 1
- Single daily dosing is standard; divided dosing (every 6-8 hours) is reserved for pain management, not standard OUD treatment 6, 5